Prescient Therapeutics Reveals Encouraging PTX-100 Trial Results

Prescient Therapeutics Limited (AU:PTX) has released an update.

Prescient Therapeutics Limited, a leading oncology company, has announced promising Phase 1b study results for PTX-100, a novel treatment for T-cell lymphomas, showing a 45% overall response rate, which surpasses current standard care. The company is poised to present these findings at the prestigious T-Cell Lymphoma Forum in California and is planning a Phase 2 trial set to commence in the third quarter of 2024. PTX-100, which has received Orphan Drug Designation from the US FDA, could signal a new era of hope for patients with limited treatment options.

For further insights into AU:PTX stock, check out TipRanks’ Stock Analysis page.